Literature DB >> 18575046

Medications in the kidney.

A J Scheen1.   

Abstract

Patients with chronic kidney disease (CKD) constitute a population at high risk for adverse drug reactions and/or drug-drug interactions. Renal dysfunction-induced pathophysiological changes may alter both medication pharmacodynamics and handling. Most pharmacokinetic parameters are adversely affected by impaired kidney function, among which reduced glomerular filtration and altered tubular secretion and reabsorption lead to the most specific alterations. Dosages of drugs cleared by the kidney should usually be adjusted according to creatinine clearance. Recommended methods for maintenance dosing adjustments are dose reductions, lengthening the dosing interval, or both. Appropriate drug selection and dosing in patients with CKD is imperative to avoid drug adverse events and to ensure optimal patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575046     DOI: 10.1179/acb.2008.63.2.003

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  3 in total

Review 1.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 2.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

Review 3.  Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatment.

Authors:  Jürgen E Scherberich; Reinhard Fünfstück; Kurt G Naber
Journal:  GMS Infect Dis       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.